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Abstract Metabolic pro¢les from 1H nuclear magnetic reso-
nance spectroscopy have been used to describe both one and two
protein systems in four mouse models related to Duchenne mus-
cular dystrophy using the pattern recognition technique partial
least squares. Robust statistical models were built for extracts
and intact cardiac tissue, distinguishing mice according to ex-
pression of dystrophin. Using metabolic pro¢les of diaphragm,
models were built describing dystrophin and utrophin, a dystro-
phin related protein, expression. Increased utrophin expression
counteracted some of the de¢cits associated with dystrophic
tissue. This suggests the method may be ideal for following
treatment regimes such as gene therapy.
% 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked re-
cessive disorder characterised by progressive muscle wasting,
leading to death from pulmonary or cardiac complications [1].
Dystrophin, a 427 kDa costameric protein, binds the actin
cytoskeleton and links it to the extracellular matrix by asso-
ciating with a large transmembrane glycoprotein complex
[2^5]. This dystrophin^glycoprotein complex is thought to
play a role in sarcolemmal stabilisation during the contraction
cycle, as absence of dystrophin renders the sarcolemma sus-
ceptible to contraction induced injury.
Utrophin is functionally analogous to dystrophin, with
both proteins possessing binding sites for actin and the dys-
trophin^glycoprotein complex, albeit through di¡erent motifs
[6]. The protein is found over the entire surface of muscle
¢bres in foetal skeletal muscle, but is replaced by dystrophin
during development, when utrophin becomes localised to the
neuromuscular junction in adult skeletal muscle [7^9]. The
dystrophic phenotype normally observed in mdx mice, a mod-
el of DMD, is absent when muscles overexpress utrophin
[10^12].
Attempts to replace the missing mutated dystrophin gene
using transgene therapy have proven di⁄cult, and are compli-
cated by the immune reaction generated by expressing dystro-
phin, a protein seen as foreign to a patient who does not
possess a functional copy of the gene [13]. For this reason
upregulation of utrophin expression in muscle is a favoured
gene therapy approach for DMD.
We have previously shown using a combination of pattern
recognition and either solution or solid state 1H nuclear mag-
netic resonance (NMR) spectroscopy that muscle and brain
tissue from mdx mice have distinct metabolic pro¢les com-
pared with control animals [14,15]. These studies used princi-
pal component analysis (PCA), an unsupervised method of
pattern recognition, to classify tissues according to metabolic
pro¢les.
The aim of this study was to investigate the metabolic pro-
¢les of cardiac and diaphragm tissue from four di¡erent
mouse models, all expressed on the same C57BL/10 back-
ground: (i) the mdx mouse which does not express dystro-
phin; (ii) Tg/Dmdmdx : transgenic mouse expressing full-length
utrophin in skeletal muscle but not heart crossed with the mdx
mouse to produce mice lacking dystrophin but having utro-
phin localised at the sarcolemma [11] ; (iii) Tgtruncated /
Dmdmdx ;utrn3=3 : transgenic mice expressing a truncated utro-
phin transgene crossed onto a Dmdmdx/utrn3=3 double mutant
background, resulting in a mouse with no dystrophin in skel-
etal muscle but with a truncated utrophin transgene and heart
with no dystrophin or utrophin [16] ; (iv) the control mice to
(iii), Tgtruncated /Dmdmdx, which have no dystrophin but express
utrophin. Prediction to latent structures through partial least
squares (PLS [17]) was used to correlate protein expression
with metabolic pro¢les. We show that distinct metabolic pro-
¢les are associated with the expression of dystrophin and
utrophin. Furthermore, this is a general approach suitable
for the investigation of other protein system.
2. Materials and methods
2.1. Materials
All mice were maintained according to the UK Home O⁄ce guide-
lines. Male 6 month old mice were removed from stable colonies of
C57BL/10 control mice (n=8 for cardiac tissue, 10 for aqueous ex-
tracts, 5 for diaphragm), mdx (n=12 for heart, 5 for diaphragm),
Tg/Dmdmdx (n=5); Tgtruncated /Dmdmdx ;utrn3=3 (n=2 for heart) and
Tgtruncated /Dmdmdx (n=2 heart) mice (Table 1). Animals were killed
by cervical dislocation, and cardiac and diaphragm tissues were re-
moved rapidly. Tissue was immediately frozen in liquid nitrogen and
stored for no longer than 24 h at 340‡C prior to NMR analysis.
Genetic integrity of the colonies was monitored throughout.
2.2. Methods
Frozen cardiac and diaphragm tissues were pulverised using a pestle
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and mortar, and metabolites extracted with a 1:1 mixture of acetoni-
trile and water (100 mg in 1 ml). The solvent was lyophilised and
extracts redissolved in D2O. All spectra were acquired in a 14.1 T
superconducting magnet interfaced to an AVANCE spectrometer
(Bruker, Karlsruhe, Germany). Solvent suppressed spectra were ac-
quired into 16k data points, averaged over 128 scans, using a pulse
sequence based on the start of a NOESY pulse sequence (relaxation
delay= 1.5 s, mixing time= 150 ms).
For solid state spectra of cardiac tissue, 10 mg of tissue was soaked
in D2O and packed into zirconium oxide rotors, with 5 Wl of D2O and
10 mM 2,2,3,3-D trimethylsilyyl, 1-propionic acid (TSP), using a rotor
spacer to ensure packing homogeneity. The rotors were spun at 5000
Hz at 300 K in a high resolution magic angle spinning (HRMAS)
probe placed in the spectrometer described above. Spectra were ac-
quired using the solvent suppressed sequence described above. Free
induction decays were collected into 16k data points and averaged
over 256 scans. Carr Purcell Meiboom and Gill (CPMG) spectra
were also acquired using a 40 ms total spin echo delay with 40 spin
echoes each of 500 Ws between the Z pulses. Continuous wave irradi-
ation was used to suppress the water resonance. Other parameters
were identical to those used with the solvent suppressed spectra de-
scribed above.
All spectra were processed using XWINNMR software (version
3.1; Bruker). Following multiplication by either a 0.3 or 1 Hz expo-
nential function for liquid and solid state spectra, respectively, spectra
were Fourier transformed from the time to frequency domain, phased
and baseline corrected.
2.3. Pattern recognition of tissue spectra
Spectra were integrated across 0.04 ppm spectral regions between
0.4 and either 4.2 or 9.4 ppm for solid and solution state NMR,
respectively, using the AMIX software package (Bruker). The output
vector representing each spectrum was normalised across the integral
regions, excluding the water resonance. Data sets were imported into
the SIMCA package (Umetrics, Umeaﬁ, Sweden) and then prepro-
cessed using three di¡erent scaling processes: (i) mean centring by
measuring the variance of each integral region about this mean,
(ii) univariate using mean centring followed by scaling the variance
by 1/sk where s is the standard deviation of the variable (integral
region) k and (iii) Pareto scaled to (1/sk)1=2.
Each integral region represented an X variable in the PLS model.
Protein expression was represented as a Y vector. For both tissue
types presence and absence of dystrophin was represented as 1 or 0
(expression or failure). For diaphragm tissue, utrophin expression was
represented by a second Y variable as 1 (normal expression) or 2
(promoted expression). The goodness of ¢t algorithm was used to
determine whether a correlation was signi¢cant (Q2s 0.097), and
how many PLS components were used in the model. Metabolic per-
turbations caused by a failure to express a protein were determined
from loadings plots. Spectral regions having a modulus loadings score
of greater than 50% of the maximum loading value for that model
were identi¢ed as having the most signi¢cant changes.
3. Results
Three data matrices were prepared using the cardiac tissue
from the ¢ve mouse strains: one derived from aqueous ex-
tracts and two investigating intact tissue. Of the two HRMAS
1H NMR spectroscopy pulse sequences used, the CPMG ex-
periment, relying on T2 attenuation of the FID, produced
spectra with most contributions from low molecular weight
metabolites while the solvent suppressed spectra were domi-
nated by lipid resonances (Fig. 1A). The three matrices rep-
resented a graduated change in environment from lipophilic to
hydrophilic. By visual inspection the spectra could not be
separated into the ¢ve groups of animals for either of the
three pulse sequences, indicating that failure to express dys-
trophin does not induce a major metabolic perturbation.
Using the solvent suppressed spectra from intact cardiac
tissue, two PLS models were built, using either univariate or
Pareto prescaling, correlating dystrophin expression to the
metabolic pro¢le for the ¢ve di¡erent mouse types (Fig. 1B;
Table 2). Pareto preprocessing identi¢ed ¢ve resonance re-
gions as being increased and seven regions as decreased in
relative spectral intensity following the expression of dystro-
phin. These resonance regions were all represented in the uni-
variate model, along with three further regions of increased
and two regions of decreased spectral intensities. Examining
the spectra, these resonance regions correlated with an increase
in lipid moieties, taurine and creatine and a decrease in glu-
cose and L-hydroxybutyrate in dystrophic tissue (Table 2).
The CPMG matrix was employed to investigate motionally
less restrained metabolites in the intact tissue. Using all three
methods of preprocessing, a one component model was
formed from the spectral intensities using the CPMG pulse
sequence as the X matrix and dystrophin expression as the Y
vector (Q2 = 0.102 (mean centred); Q2 = 0.169 (Pareto; Fig.
1B(2)); Q2 = 0.197 (univariate)). A total of 15 spectral regions
were found to contribute to at least 50% of the maximum
loadings score across the three models (Table 2).
The aqueous extract spectral matrix was most discriminat-
ing in terms of dystrophin expression. All three preprocessing
routines gave signi¢cant models for a PLS analysis of the
metabolic pro¢les in terms of protein expression. Both uni-
variate (Q2 = 0.181) and Pareto (Q2 = 0.230; Fig. 1B(3)) pre-
processing produced PLS models with one component, while
mean centred preprocessing produced a two component mod-
el (cumulative Q2 = 0.509). In total 22 spectral regions were
identi¢ed as contributing to the separation at 50% or greater
of the maximum loadings contribution. In keeping with the
mathematical basis of the three preprocessing techniques, Pa-
reto scaling provided a half way point between the two ex-
tremes of no scaling and univariate scaling. Intriguingly, one
Table 1
Summary of mouse models used in this study
Mouse strain Heart Skeletal muscle and
diaphragm
Phenotype
Dys Utr Dys Utr
C57BL/10 control + + + + Normal
Mdx 3 + 3 + Mild cardiac hypertrophy, V60% centrally nucleated ¢bres in
diaphragm
Tg/Dmdmdx 3 + 3 ++ No di¡erence from control tissue
Tgtruncated /DMDmdx 3 + 3 ++ Some increase in centrally nucleated ¢bres in skeletal muscles and
diaphragm
Tgtruncated /Dmdmdx ;utrn3=3 3 3 3 + (trun) Marked myopathy, premature death, connective tissue
proliferation, waddling gait, arched spine
Phenotype information is from [11,12,31]. Dystrophin (dys) and utrophin (utr) expression are measured in relative terms: + normal expression,
++ increased, 3 decreased, trun truncated.
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metabolite, L-hydroxybutyrate, was consistently decreased in
dystrophic intact cardiac tissue but increased in the aqueous
extract, suggesting an ‘NMR invisible pool’, possibly mito-
chondrial.
To further examine the Pareto preprocessed data set a series
of further models were built. Orthogonal signal correction
(OSC) was applied using dystrophin expression as the Y vec-
tor for this data ¢ltering technique. Extracting two compo-
nents of data not correlated to dystrophin expression pro-
duced a data set representing 33% of the remaining
variation. Using this data set, a PLS model was built corre-
lated to protein expression, with a goodness of ¢t algorithm of
Q2 = 0.875, explaining 47% of the remaining spectral variation
and 97% of the variation produced in mapping protein ex-
pression to Y=0 or 1. In addition to the metabolites identi¢ed
in the pre-OSC ¢ltered data set, two further regions were
identi¢ed (N=3.06, 3.94) corresponding to creatine. Applying
PCA to the OSC ¢ltered data set, separation was most appar-
ent in the ¢rst two components which represented 93% of the
remaining spectral variation and a goodness of ¢t of
Q2 = 0.682 (Fig. 2). Spectral regions identical to the PLS anal-
ysis were identi¢ed as contributing signi¢cantly to the separa-
tion.
To test model robustness, PLS was used to predict dystro-
phin expression in a subset of the extract spectra. The data set
was preprocessed using Pareto scaling, and random selections
of spectra were excluded for four di¡erent models (six out of
the 31 spectra). The resulting PLS models had a combined
success rate of 96V 7% (equivalent to one incorrectly assigned
spectrum out of the four models). To examine how the
technique would predict new mouse models for DMD,
Tg/Dmdmdx and a combination of Tgtruncated /Dmdmdx ;utrn3=3
and Tgtruncated /Dmdmdx were excluded separately from di¡erent
PLS models built using the remainder of the data (26 and 27
spectra, respectively), with the prediction success being 80%
and 75%, respectively (in both cases one spectrum was
misclassi¢ed in each model built). The mean Y PLS scores
for Tg/Dmdmdx were 0.22V 0.18, and for Tgtruncated /Dmdmdx ;
utrn3=3 and Tgtruncated /Dmdmdx 0.32V 0.13.
3.1. Building a two component model for the diaphragm
Having shown that failure to express dystrophin was asso-
Fig. 1. Intact tissue and aqueous extracts of cardiac tissue were investigated by 1H NMR spectroscopy. Three data matrices were formed from
high resolution spectra (A) taken from intact tissue using either a standard pulse and acquire sequence (top) or a T2 edited pulse sequence with
a total relaxation time of 40 ms (middle), or from acetonitrile/water extracts of the tissue (bottom). PLS regression models were built (B; all
with Pareto prescaling) modelling expression of changes in metabolic pro¢le against dystrophin expression. The loadings plots (C) for these
models were used to distinguish which metabolites were the most signi¢cant in terms of describing this separation. Key: 1. CH3CH2^ lipid
groups, 2. L-hydroxybutyrate, 3. CH2CH2 lipid, 4. lactate, 5. alanine, 6. glutamate, 7. CH2CH2CHNCH lipid groups, 8. creatine, 9. taurine.
a control; F mdx ; b Tg/Dmdmdx ; 8 Tg/Dmdmdx ;utrn3=3 ; R Tgtruncated /DMDmdx.
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Table 2
Metabolites increased or decreased in dystrophic cardiac tissue compared to the normal group for the PLS models built
Pulse sequence Scaling of data Q2 Metabolites increased Metabolites decreased
HRMAS solvent suppress Univariate 0.26 CH3CH2 lipid (1.0), lactate, (1.34), CH2CNC (2.1^2.0), glutamate
(2.36), CNCCH2CNC (2.78), lysine (3.02), taurine (3.26, 3.46)
Glucose (3.5^3.86), choline (3.20), malonate (3.13), L-hydroxybutyrate
(1.20), cholesterol (0.78)
Pareto 0.34 Taurine (3.26, 3.46), CH2CNC (2.1^2.0), lactate (1.34), CH3CH2
lipid (0.9)
Choline (3.20), malonate (3.13), L-hydroxybutyrate (1.20), cholesterol
(0.78)
Mean centred No ¢t
HRMAS CPMG Univariate 0.30 CH2CNC (2.1^2.0), CH2CH2CO (1.58), lactate (1.34, 4.14),
CH2CH2CH2 lipids (1.32^1.27), CH3CH2 lipids (0.90)
Glucose (3.50^3.70), K-ketoglutarate (2.45), acetate (1.94),
CH2CH2CNC (1.74^1.70), L-hydroxybutyrate (1.20)
Pareto 0.43 Taurine (3.26), glutamate (2.38), lactate (1.34) L-Hydroxybutyrate (1.16)
Mean centred 0.10 Taurine (3.26), lactate (1.34)
Aqueous extract Univariate 0.18 ATP (8.58), inosine (8.3), glycerol (4.02, 3.56), L-hydroxybutyrate
(1.16), n-butyrate (0.90)
Dimethylglycine (2.82), aspartate (2.68), glutamine (2.22, 2.10),
acetate (1.90), leucine (1.70), lysine (1.74), leucine, isoleucine, valine
(0.98^0.94)
Pareto 0.23 Taurine (3.42), lactate (1.34), L-hydroxybutyrate (1.16) Glutamine (2.22), glutamate (2.06), isoleucine/leucine (0.94^0.98)
Mean centred 0.51 Taurine (3.42), lactate (1.34), L-hydroxybutyrate (1.16) Creatine (3.06, 3.94), glutamate (2.06)
Chemical shifts are shown in parentheses.
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The loadings score for each PLS component indicated the
key metabolites perturbed by a change in protein expression.
The upregulated utrophin expression in Tg/Dmdmdx mice
showed decreased concentrations of glycerol, creatine and glu-
cose and increased concentrations of short chain fatty acids
and L-hydroxybutyrate in diaphragm tissue (Table 3). Again,
as in cardiac tissue, taurine appeared to be a signi¢cant bio-
marker for dystrophin expression. Examining contribution
scores for the PLS component modelling dystrophin expres-
sion, tissue extracts from Tg/Dmdmdx mice demonstrated met-
abolic pro¢les intermediate between the control and mdx
mouse. This suggests that promoting utrophin expression
can negate the metabolic e¡ects of a failure to express dystro-
phin.
3.2. Temporal progression of metabolites in mdx and
control mice
The above PLS models were all built using spectra from
animals agedV6 months old. However, metabolite pool sizes
also vary with development and during ageing. Thus, spectral
variation with age was investigated in tissue extracts from
C57BL/10 control and mdx mice using PLS with Pareto scal-
ing (n=3 for 3, 6, 10 and 15 month ages). For both dia-
phragm and cardiac tissue one component models were built
indicating that for both mouse strains there was a temporal
progression in metabolites (Fig. 4). However, this progression
was di¡erent between strains. In cardiac and diaphragm tissue
from mdx mice, the concentrations of L-hydroxybutyrate, cre-
atine and taurine resonances decreased and lactate increased
with age. The age related changes were less de¢ned in control
Fig. 3. A two component PLS model was built to examine the met-
abolic pro¢le of diaphragm tissue in terms of dystrophin and utro-
phin expression. A: High resolution 1H NMR spectra of aqueous
extracts were used as the X inputs to the PLS model. The acetoni-
trile/water mixture also extracted small chain lipids. B: A two com-
ponent PLS model (Pareto scaled data shown). C: Loadings plots
were derived for utrophin (top) and dystrophin (bottom) showing
which metabolites contributed most to the model. Key: 1. CH3CH2
lipid, 2. leucine, valine and isoleucine, 3. L-hydroxybutyrate,
4. CH2CH2 lipids, 5. lactate, 6. alanine, 7. CH2CH2CO lipid
groups, 8. CH2CH2CHNCH, 9. CH2CHNCH lipid, 10. glutamate,
11. creatine, 12. taurine. a control; F mdx ; b Tg/Dmdmdx.
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spectra, as determined by the contribution scores of individual
metabolites and the Q2 of the model, and were caused by a
decrease in lactate and an increase in glucose concentrations
with age. However, for all the spectra from a given strain, the
di¡erences between strain were greater than those caused by
age as measured by PCA or PLS techniques (Fig. 4), with
dystrophic tissue having an increased concentration of taurine
and a decrease in creatine.
4. Discussion
Somatic manipulation of the genome of models of DMD
has produced poor results, and current treatment strategies
have focused on upregulating DRP proteins to compensate
for the missing dystrophin. Central to these strategies is an
understanding of gene expressions in terms of their functional
responses. This is a particular challenge for the mdx mouse,
and related models, where the disease phenotype is mild in
comparison to humans. In this study we have used PLS, a
supervised pattern recognition technique, to perform regres-
sions between metabolic pro¢le and protein expression in car-
diac and diaphragm tissue. Despite their di¡erent genotype a
common metabolic de¢cit was identi¢ed across the mouse
models used in this study.
Although not primarily a metabolic disorder, dystrophic
muscle tissue is characterised by perturbed metabolism
[18^21]. We have previously demonstrated using PCA of
1H NMR spectra of tissue extracts that a range of tissues
from mdx mice have distinct metabolic pro¢les compared to
control siblings both in tissue extracts [14] and in intact car-
diac tissue [15]. Many of the metabolites identi¢ed as being
altered in cardiac tissue have been identi¢ed previously using
PCA of mdx tissue alone, including an increase in lipid chain
length, increased concentration of the non-polar amino acids
leucine, valine and isoleucine and an increased concentration
of taurine. The concentration of taurine has also been previ-
ously correlated with muscle regeneration following necrosis
[20,21]. However, a number of metabolites had not previously
been identi¢ed, including n-butyrate and glycerol, indicative
of a failure to process ketone bodies and fatty acid deriva-
tives. Unlike the classi¢cation tool PCA, this approach could
also be used to predict gene expression. Using the data set
derived from cardiac tissue extracts we were able to demon-
strate that models could be built capable of classifying test
data, even for new mouse models of the disease that had not
been included in the building of the model.
Tg/Dmdmdx mice do not express dystrophin, but have pro-
moted utrophin expression in skeletal muscle and diaphragm
(but not cardiac muscle). This allowed the formation of a PLS
model where two proteins were correlated with metabolic phe-
Fig. 4. A: PLS models were built to examine age related metabolite changes in extracts of cardiac tissue from mdx and C57BL/10 control mice
between 3 and 15 months. Each point represents the mean PLS scoreV S.D. (n=3). Plotted against time, the PLS scores for dystrophic tissue
displayed an almost linear response, while the PLS scores in control tissue from 15 month old animals displayed the largest perturbation.
B: Despite these changes control (a) and dystrophic (F) tissue can be readily distinguished using PCA or PLS (shown). The two control spec-
tra found in the most extreme left of the plot are from 15 month old animals.
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notype. Control and mdx diaphragm tissue was readily sepa-
rated across one PLS component caused by a series of
changes including an increase in the concentration of taurine.
The increased utrophin expression in Tg/Dmdmdx mice also
in£uenced small molecule metabolism, with diaphragm tissue
having increased concentrations of lactate and alanine com-
pared with both mdx and control diaphragm tissue.
However, more intriguingly the mean scores for the
PLS component correlated to dystrophin expression for
Tg/Dmdmdx diaphragm tissue was intermediate between the
mdx and control mouse tissue. The ¢rst wave of muscle ne-
crosis only occurs in dystrophic tissue when utrophin expres-
sion falls below that found in neonatal muscle. Tinsley and
co-workers [11] have demonstrated that increased utrophin
expression reverses the phenotype characteristic of mdx mouse
muscle tissue. In our study we have also found evidence of the
bene¢cial action of promoted utrophin expression in dystro-
phic tissue in terms of the metabolic phenotype produced. A
number of treatments for DMD have been suggested, includ-
ing temporary changes in protein expression [22^24], amino-
glycosides that suppress stop mutations [25], the introduction
of stem cells [26] or the targeting of promoter and enhancer
regions of the utrophin gene [27^29]. PLS derived metabolic
pro¢les may be used for screening other potential molecular
activating factors. Although the ¢eld strengths used in this
study are higher than that used in clinical systems, 9.4 and
11.7 T experimental in vivo systems are increasingly common
for studying mice and rats. Alternatively, human muscle tissue
removed by biopsy may be monitored using HRMAS 1H
NMR spectroscopy as described in this study.
The techniques described in this study may be useful for
following a range of protein changes as measured by proteo-
mics. There are a number of dystrophin related proteins other
than utrophin, and the failure to express dystrophin also af-
fects expression of proteins in the dystrophin^glycoprotein
complex. With further animal models of related disorders
[30] the action of dystrophin related proteins and dystro-
phin^glycoprotein complex proteins could be modelled in
terms of metabolic phenotypes. In addition, mouse models
of Beckers muscular dystrophy could be examined to inves-
tigate the e¡ects of impaired dystrophin expression, rather
than lack of expression. The inclusion of a model of cardiac
hypertrophy may also shed light on the mechanisms involved
in muscle failure in the mdx mouse. Although cardiac hyper-
trophy is mild at 6 months in mdx mice [31], some of the
metabolic changes detected at this time point may be indica-
tive of the early stages of this disease. However, by using four
di¡erent models of DMD, each with di¡erent severities of
cardiac and muscular abnormalities, the metabolic changes
detected appear associated with dystrophin and utrophin ex-
pression rather than cardiac hypertrophy or cellular prolifer-
ation after necrosis. McIntosh and co-workers have previously
correlated cardiac taurine concentrations with regeneration
and myogenic cell proliferation in mdx mice, mice de¢cient
in the early myogenic regulatory gene (MyoD) and the double
mutant mdx :MyoD(3/3) cross strain [20]. While no ‘omic’
approach can separate the causes and consequences of a phe-
notype from the transcriptome, proteome or metabolon, it
may be possible to use related mouse models to interrogate
which pathways are common to given events such as muscular
hypertrophy [31^33], cellular proliferation and muscle repair
[20,21,34] and muscular denervation and reinnervation [35].
For such studies metabolomics provides a cheaper alternative
to transcriptomics and proteomics.
The techniques used in our study are not con¢ned to this
application, or mammalian systems. Such metabonomic/me-
tabolomic approaches have been used in the study of drug
toxicology [36], probing ‘silent phenotypes’ in yeast cells
[37], or alternatively, the already characterised Caenorhabditis
elegans model of DMD [38], where the dystrophin analogue
dys-1 has been knocked out, could be used to screen for small
molecules which promote upregulation of dystrophin related
proteins in this animal.
In conclusion, we have demonstrated that a failure to ex-
press dystrophin in cardiac and diaphragm muscle produces
metabolic phenotypes distinct to the protein, and this may be
used to characterise new models of the disease. These models
also predict that increased utrophin expression may prevent
some of the metabolic de¢cits associated with dystrophic tis-
sue.
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